Therapeutic Efficacy of Transcatheter Arterial Chemoembolization as Compared With Hepatic Resection in Hepatocellular Carcinoma Patients With Compensated Liver Function in a Hepatitis B Virus–Endemic Area: A Prospective Cohort Study

Abstract

TACE proved to be as effective as HR in the subpopulations with UICC T3N0M0 or CLIP 1-2 HCC and adequate liver function, and even with UICC T1-2N0M0 HCC when lipiodol was compactly retained in the tumor. In such cases, the choice of treatment modality between TACE and HR may be left to the patient's preference.

Hepatic Resection after Initial Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for the Treatment of Hepatocellular Carcinoma: A Meta-analysis of Observational Studies

“…Overall, 2037 papers were initially retrieved, of which 3 were included (Eurvilaichit and Kanjanapitak, 2000;Lee et al, 2002;Liu et al, 2007) (Figure 1). Study characteristics were shown in Table 1.…”

“…In an individual study by Lee et al, the survival benefit of hepatic resection after initial TACE should be attributed to the subgroup of patients at less advanced tumor stages (Lee et al, 2002). The investigators conducted the subgroup analyses according to the International Union Against Cancer (UICC) stage and the Cancer of the Liver Italian Program (CLIP) scoring system.…”

The Role of Interventional Radiology in the Management of Hepatocellular Carcinoma

“…Lee et al compared tace with surgical resection in a large study 94 in which 91 patients underwent resection and 91 received multiple sessions of tace. The survival rate was significantly higher with liver resection than with tace (p = 0.0038), median survival time being 66 months and 37 months respectively.…”

Common and separate origins of the left and right inferior phrenic artery with a review of the literature

“…In particular, transcatheter arterial chemoembolization is widely used to manage unresectable hepatocellular carcinoma. Extrahepatic collateral arteries supply the hepatocellular carcinoma, even when the hepatic artery is patent [14]. This stems largely from the discovery of the involvement of the IPAs in the arterial supply and growth of hepatocellular carcinoma [5,27].…”